when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Vera Therapeutics, Inc. ($VERA) · news · pharmadog

← back to Vera Therapeutics, Inc.

News mentioning $VERA

64 stories

11dRoche, Ionis RNA drug scores in kidney disease studybiopharma dive

12dRoche kidney drug's Phase 3 win sets up path to accelerated approvalendpoints

18dSTAT+: New startup to test psychedelic-like drug against Parkinson’s symptomstat

19dSTAT+: Sen. Warren demands to see Trump drug-pricing pharma contracts, accuses RFK Jr. of hiding themstat

19dU.S. reaches highest number of measles deaths in decadesstat

19d5 biotechs braving the commercial waters with product launchesbiospace

20dSTAT+: Obesity drugmakers are testing in kids as young as 6stat

20dVera eyes full approval for Trutakna in IgAN following positive readoutendpoints

20dSTAT+: Vera kidney drug Trutakna shows strong final results in Phase 3 trialstat

24dDisc sets up polycythemia vera challenge but Silence maintains leadbiospace

24dTakeda’s long-term R&D head announces exit after major pipeline reorganizationbiospace

Aug 31, 26FDA OKs Takeda, Protagonist drug for rare blood cancerbiopharma dive

Aug 31, 26STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and morestat

Aug 31, 26Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunitybiospace

Aug 30, 26STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancerstat

Aug 28, 26FDA approves Takeda, Protagonist drug for rare blood disorderendpoints

Aug 28, 26FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorderfda press

Aug 17, 26Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxactbiospace

Aug 14, 26Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myersbiopharma dive

Aug 13, 26Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100Mbiospace

Aug 13, 26Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionfiercebiotech

Aug 12, 26Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccinesbiopharma dive

Aug 12, 26Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drugendpoints

Aug 12, 26Boulevard starts up with $65M to pursue targeted autoimmune drugsbiopharma dive

Aug 11, 26Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugsfiercebiotech

Aug 11, 26Silence causes uproar in rare blood cancer space as data sets high bar for competitorsbiospace

Aug 10, 26Silence spells out Phase 2 success for gene-silencing drug in rare blood cancerendpoints

Aug 10, 26STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancerstat

Aug 10, 26Silence brings the noise to Takeda with phase 2 blood cancer winfiercebiotech

Aug 7, 26Why Big Pharma is chasing the industry’s most-powerful supercomputerbiopharma dive

← prevpage 1 of 3next →